Recent Updates
Recently added Catalysts
FATE Neutral Sentiment Score: 50/100

Treatment of Refractory SLE with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy

Key Takeaway: The article discusses the treatment of refractory systemic lupus erythematosus (SLE) using off-the-shelf iPSC-derived anti-CD19 CAR T-cell therapy. It highlights the potential benefits of this innovative approach but does not provide specific results or outcomes. The focus is on the therapy's application and relevance in treating this challenging condition.
Price reaction · baseline $1.67 (2025-06-10 close) · hit pre-market · clean, no other FATE news in the window
day 0 close
-7.2%
day 1
-16.2%
day 3 · peak
-25.7%

Market Sentiment Analysis

Full Press Release Details

• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Last updated: Jun 11, 2025